Prophylactic hyperthermic intraperitoneal chemotherapy can be considered in the management of advanced gastric cancer

We read with interest the article by Dehal, Smith and Nash (1), intitled “Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review—past, present and future” and, also congratulating them for the comprehensive review performed, we believe that, the role that hyperthermic intraperitoneal chemotherapy (HIPEC) can play in the prophylaxis of peritoneal carcinomatosis (PC) in patients with gastric cancer, should be emphasized